Global Drugs Based on CAR T-cell Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs Based on CAR T-cell Market Research Report 2024
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer
According to Mr Accuracy reports new survey, global Drugs Based on CAR T-cell market is projected to reach US$ 19640 million in 2029, increasing from US$ 2805.8 million in 2022, with the CAGR of 29.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs Based on CAR T-cell market research.
The CAR T-cell therapy drug gel market is driven by the revolutionary approach of CAR T-cell therapy in cancer treatment and the demand for targeted and personalized therapies. CAR T-cell therapy involves genetically modifying a patient's own T cells to target and destroy cancer cells. The rise in cancer prevalence and the need for innovative treatments contribute to market growth as healthcare providers seek effective and tailored solutions for patients with difficult-to-treat cancers. Moreover, advancements in gel-based drug delivery systems have improved the precision and safety of CAR T-cell therapy administration. However, the market also faces challenges, including complex manufacturing processes and potential side effects associated with immune response. Additionally, addressing the high cost of CAR T-cell therapies and ensuring scalability and accessibility for broader patient populations can pose obstacles for manufacturers and healthcare systems. To succeed, companies must focus on advancing research and development, collaborating with oncologists to optimize therapy protocols, and addressing the challenges to meet the increasing demand for breakthrough cancer treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs Based on CAR T-cell market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
Segment by Type
CD19-targeted
BCMA-targeted
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Drugs Based on CAR T-cell report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Drugs Based on CAR T-cell market is projected to reach US$ 19640 million in 2029, increasing from US$ 2805.8 million in 2022, with the CAGR of 29.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs Based on CAR T-cell market research.
The CAR T-cell therapy drug gel market is driven by the revolutionary approach of CAR T-cell therapy in cancer treatment and the demand for targeted and personalized therapies. CAR T-cell therapy involves genetically modifying a patient's own T cells to target and destroy cancer cells. The rise in cancer prevalence and the need for innovative treatments contribute to market growth as healthcare providers seek effective and tailored solutions for patients with difficult-to-treat cancers. Moreover, advancements in gel-based drug delivery systems have improved the precision and safety of CAR T-cell therapy administration. However, the market also faces challenges, including complex manufacturing processes and potential side effects associated with immune response. Additionally, addressing the high cost of CAR T-cell therapies and ensuring scalability and accessibility for broader patient populations can pose obstacles for manufacturers and healthcare systems. To succeed, companies must focus on advancing research and development, collaborating with oncologists to optimize therapy protocols, and addressing the challenges to meet the increasing demand for breakthrough cancer treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs Based on CAR T-cell market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
Segment by Type
CD19-targeted
BCMA-targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Drugs Based on CAR T-cell report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source